Tuesday, July 19, 2016

UPDATE 2-Zafgen to scrap lead obesity drug, shares slide

July 19 (Reuters) - Zafgen Inc said it was

suspending the development of its lead obesity drug, beloranib,

more than six months after the U.S. Food and Drug Administration

asked the company to halt...

Read more
Posted by at

No comments:

Post a Comment

Subscribe to: Post Comments (Atom)